Stockreport

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics, Inc.  (TRDA) 
PDF – Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2 [Read more]